| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Date of Report (date of earliest event reported): November 16, 2026 |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy |
| 19 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
1.He is the Chief Executive Officer and Chief Scientific Officer of iBio, Inc. (the “Corporation”), a Delaware corporation, and is duly authorized by the Board of Directors of the Corporation to execute this instrument. |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION • September 2026 |
| 28 Aug 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its ... |
| 04 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL |
| 17 Jul 2026 |
8-K: Shareholder Director Nominations; Other Events
To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08. |
| 01 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Received regulatory clearance to initiate its phase 1 clinical trial of IBIO-600 in Australia |
| 08 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
San Diego, California / May 8, 2026 / (GLOBE NEWSWIRE) / -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Ston... |
| 08 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
BREAKTHROUGH ANTIBODIES FOR OBESITY AND CARDIOMETABOLIC DISEASES CORPORATE PRESENTATION March 2026 |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement
On February 27, 2026, iBio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale AgreementSM (the “ATM Agreement”) with Jefferies LLC (“Jefferies”) providing for the sale by the Company of its shares of common s... |
| 10 Feb 2026 |
8-K: Results of Operations and Financial Condition
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 8, 2026, by and among iBio, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Inv... |
| 21 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On November 20, 2025, iBio, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on four (4) proposals and cast their votes as described below. A tot... |
| 17 Nov 2025 |
8-K: Regulation FD Disclosure; Other Events
iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K. |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds |
| 04 Nov 2025 |
8-K: Other Events
On November 4, 2025, iBio, Inc. (the “Company”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) noting it has regained compliance with Nasdaq Lising Rule 5550(a)(2). As previously repo... |
Loading...